Small Cell Lung Cancer with Liver Metastases: from Underlying Mechanisms to Treatment Strategies

Overview

Journal Cancer Metastasis Rev

Specialty Oncology

Date 2024 Nov 25

PMID 39585433

Authors

Linjie Fan

Yiwen Lin

Yunjie Fu

Jie Wang

Affiliations

Soon will be listed here.

Abstract

Small cell lung cancer (SCLC) represents an aggressive neuroendocrine (NE) tumor within the pulmonary region, characterized by very poor prognoses. Druggable targets for SCLC remain limited, thereby constraining treatment options available to patients. Immuno-chemotherapy has emerged as a pivotal therapeutic strategy for extensive-stage SCLC (ES-SCLC), yet it fails to confer significant efficacy in cases involving liver metastases (LMs) originating from SCLC. Therefore, our attention is directed towards the challenging subset of SCLC patients with LMs. Disease progression of LM-SCLC patients is affected by various factors in the tumor microenvironment (TME), including immune cells, blood vessels, inflammatory mediators, metabolites, and NE substances. Beyond standard immuno-chemotherapy, ongoing efforts to manage LMs in SCLC encompass anti-angiogenic therapy, radiotherapy, microwave ablation (MWA) / radiofrequency ablation (RFA), trans-arterial chemoembolization (TACE), and systemic therapies in conjunction with local interventions. Prospective experimental and clinical investigations into SCLC should prioritize precise and individualized approaches to enhance the prognosis across distinct patient cohorts.

References

Tseng J, Chiang C, Chen K, Zheng Z, Yang T, Lee W . Association of Smoking With Patient Characteristics and Outcomes in Small Cell Lung Carcinoma, 2011-2018. JAMA Netw Open. 2022; 5(3):e224830. PMC: 8968543. DOI: 10.1001/jamanetworkopen.2022.4830. View

Karachaliou N, Sosa A, Rosell R . Unraveling the genomic complexity of small cell lung cancer. Transl Lung Cancer Res. 2016; 5(4):363-6. PMC: 5009089. DOI: 10.21037/tlcr.2016.07.02. View

Frese K, Simpson K, Dive C . Small cell lung cancer enters the era of precision medicine. Cancer Cell. 2021; 39(3):297-299. DOI: 10.1016/j.ccell.2021.02.002. View

Gazdar A, Bunn P, Minna J . Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017; 17(12):725-737. DOI: 10.1038/nrc.2017.87. View

Rudin C, Brambilla E, Faivre-Finn C, Sage J . Small-cell lung cancer. Nat Rev Dis Primers. 2021; 7(1):3. PMC: 8177722. DOI: 10.1038/s41572-020-00235-0. View

Riihimaki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J . Metastatic sites and survival in lung cancer. Lung Cancer. 2014; 86(1):78-84. DOI: 10.1016/j.lungcan.2014.07.020. View

Tsilimigras D, Brodt P, Clavien P, Muschel R, DAngelica M, Endo I . Liver metastases. Nat Rev Dis Primers. 2021; 7(1):27. DOI: 10.1038/s41572-021-00261-6. View

Ren Y, Dai C, Zheng H, Zhou F, She Y, Jiang G . Prognostic effect of liver metastasis in lung cancer patients with distant metastasis. Oncotarget. 2016; 7(33):53245-53253. PMC: 5288182. DOI: 10.18632/oncotarget.10644. View

Dasgupta A, Lim A, Ghajar C . Circulating and disseminated tumor cells: harbingers or initiators of metastasis?. Mol Oncol. 2017; 11(1):40-61. PMC: 5423226. DOI: 10.1002/1878-0261.12022. View

10.

Liu X, Li C, Li J, Yu T, Zhou G, Cheng J . Detection of CTCs in portal vein was associated with intrahepatic metastases and prognosis in patients with advanced pancreatic cancer. J Cancer. 2018; 9(11):2038-2045. PMC: 5995938. DOI: 10.7150/jca.23989. View

11.

Urabe F, Patil K, Ramm G, Ochiya T, Soekmadji C . Extracellular vesicles in the development of organ-specific metastasis. J Extracell Vesicles. 2021; 10(9):e12125. PMC: 8287318. DOI: 10.1002/jev2.12125. View

12.

Deneve E, Riethdorf S, Ramos J, Nocca D, Coffy A, Daures J . Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin Chem. 2013; 59(9):1384-92. DOI: 10.1373/clinchem.2013.202846. View

13.

Li T, Qiao T . Unraveling tumor microenvironment of small-cell lung cancer: Implications for immunotherapy. Semin Cancer Biol. 2022; 86(Pt 2):117-125. DOI: 10.1016/j.semcancer.2022.09.005. View

14.

Jin T, Dai C, Xu F . Surgical and local treatment of hepatic metastasis in pancreatic ductal adenocarcinoma: recent advances and future prospects. Ther Adv Med Oncol. 2020; 12:1758835920933034. PMC: 7313332. DOI: 10.1177/1758835920933034. View

15.

Li W, Zhou J, Zhang T, Tai Y, Xu Y, Bai Y . A novel score system for predicting conversion to no evidence of Disease (C-NED) in initially unresectable colorectal cancer liver metastases. Am J Cancer Res. 2022; 12(4):1648-1659. PMC: 9077072. View

16.

Gurusamy K, Corrigan N, Croft J, Twiddy M, Morris S, Woodward N . Liver resection surgery versus thermal ablation for colorectal LiVer MetAstases (LAVA): study protocol for a randomised controlled trial. Trials. 2018; 19(1):105. PMC: 5811975. DOI: 10.1186/s13063-018-2499-5. View

17.

Mahnken A, Pereira P, De Baere T . Interventional oncologic approaches to liver metastases. Radiology. 2013; 266(2):407-30. DOI: 10.1148/radiol.12112544. View

18.

Vogl T, Marko C, Langenbach M, Naguib N, Filmann N, Hammerstingl R . Transarterial chemoembolization of colorectal cancer liver metastasis: improved tumor response by DSM-TACE versus conventional TACE, a prospective, randomized, single-center trial. Eur Radiol. 2020; 31(4):2242-2251. DOI: 10.1007/s00330-020-07253-2. View

19.

Farago A, Keane F . Current standards for clinical management of small cell lung cancer. Transl Lung Cancer Res. 2018; 7(1):69-79. PMC: 5835595. DOI: 10.21037/tlcr.2018.01.16. View

20.

Zugazagoitia J, Paz-Ares L . Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options. J Clin Oncol. 2022; 40(6):671-680. DOI: 10.1200/JCO.21.01881. View